Uppsala 12thDecember 2018


Nanexa receives notification of imminent US patent grant


The US patent office has now issued an “Issue Notification” in respect Nanexa´s US patent application regarding the Company’s drug delivery platform PharmaShell®.  Although, technically-speaking, a patent can be withdrawn from issuance at any time up to the actual grant, should new information come to light, all being well, the Issue Notification states that a patent will issue on January 1, 2019 as US 10,166,198.


Nanexa’s CEO David Westberg comments:

The next step of the US Patent Office’s granting process has now taken place.  We look forward to obtaining an issued US patent for PharmaShell® in accordance with the estimated timeline.


For further information:

Nanexa AB (publ)

David Westberg, VD

Phone: +46 709 42 83 03

E mail:


About Nanexa AB (publ)

Nanexa AB is a nanotechnology drug delivery company focusing on the development of PharmaShell®, which is a new and groundbreaking drug delivery system that is expected to have great potential in a number of medical indications. Within the framework of PharmaShell®, Nanexa has partnership agreements with among others, AstraZeneca.